ANVS - Annovis Bio

-

$undefined

N/A

(N/A)

Annovis Bio NEW YORK STOCK EXCHANGE INC.:ANVS Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). The Comapny's believes that it is the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The Company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. The Company has two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients.

Location: 1055 Westlakes Dr Ste 300, Pennsylvania, 19312-2410, US | Website: www.annovisbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

69.87M

Cash

12.64M

Avg Qtr Burn

-5.744M

Short % of Float

12.88%

Insider Ownership

20.40%

Institutional Own.

8.83%

Qtr Updated

09/30/24